Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19

NCT05074420 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05074420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05074420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
December 21, 2021
Completion date
November 4, 2024
Enrollment
6 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid19